Ginseng saponins and the treatment of osteoporosis: Mini literature review

Journal of Ginseng Research

Volumn 37, Issue 3, 2013, Pages 261-268

  Siddiqi, Muhammad Hanif ^a   Siddiqi, Muhammad Zubair ^a   Ahn, Sungeun ^a   Kang, Sera ^a   Kim, Yeon Ju ^a   Sathishkumar, Natarajan ^a   Yang, Dong Uk ^a   Yang, Deok Chun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Bone morphogenetic protein 2; Ginsenosides; Osteoporosis; Panax ginseng; Receptor activator of nuclear factor kappa B ligand

Indexed keywords

EID: 84880059419     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.5142/jgr.2013.37.261     Document Type: Review

References (61)

1. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342
3. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
4. Soltanoff CS, Yang S, Chen W, Li YP. Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr 2009;19:1-46.
5. Huang W, Yang S, Shao J, Li YP. Signaling and transcrip-tional regulation in osteoblast commitment and differentiation. Front Biosci 2007;12:3068-3092
6. Kogianni G, Noble BS. The biology of osteocytes. Curr Osteoporos Rep 2007;5:81-86.
7. Raisz LG. Pathogenesis of osteoporosis: concepts, conficts, and prospects. J Clin Invest 2005;115:3318-3325
8. Ng KW. Future developments in osteoporosis therapy. Endocr Metab Immune Disord Drug Targets 2009;9:371-384.
9. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
10. National Osteoporosis Foundation. Learn about osteoporosis. Available from: http://www.nof.org/node/40.
11. World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Available from: http://www.who.int/chp/topics/Osteopo-rosis.pdf.
12. Lau RY, Guo X. A review on current osteoporosis research: with special focus on disuse bone loss. J Osteopo-ros 2011;2011:293808.
13. Narducci P, Nicolin V. Differentiation of activated mono-cytes into osteoclast-like cells on a hydroxyapatite substrate: an in vitro study. Ann Anat 2009;191:349-355.
14. Baron R, Neff L, Vignery A. Differentiation and functional characteristics of osteoclasts. Bone 1985;6:414.
15. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S et al. Osteoprotegerin ligand is a cytokine that regulates os-teoclast differentiation and activation. Cell 1998;93:165-176.
16. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosa-ki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-3602.
18. Du J, Cheng B, Zhu X, Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid effcacy with reduced side effects. J Immunol 2011;187:942-950.
19. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Ko-bayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758-763.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
21. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
22. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024.
23. Boyce BF, Xing L. Biology of RANK, RANKL, and os-teoprotegerin. Arthritis Res Ther 2007;9 SUPPL. 1:S1.
24. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178.
25. Jayakumar P, Di Silvio L. Osteoblasts in bone tissue engineering. Proc Inst Mech Eng H 2010;224:1415-1440.
26. Derynck R, Zhang Y. Intracellular signalling: the mad way to do it. Curr Biol 1996;6:1226-1229.
27. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8:133-146.
28. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947-950.
29. Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev 1994;4:737-744.
30. Berridge M. Cell signaling biology. Available from: http://www.biochemj.org/csb.
31. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241.
32. Yamashita H, Ten Dijke P, Heldin CH, Myazono K. Bone morphogenetic protein receptors. Bone 1996;19:569-574.
33. Merck. Fosamax (alendronate sodium) tablets and oral solution prescribing information. Whitehouse Station: Merck, 2011.
34. Novartis Pharmaceuticals Corporation. Reclast (zoledron-ic acid) injection prescribing information. East Hanover: Novartis Pharmaceuticals Corporation, 2011.
35. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
36. Hwang JT, Kim SH, Lee MS, Kim SH, Yang HJ, Kim MJ, Kim HS, Ha J, Kim MS, Kwon DY Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 2007;364:1002-1008.
37. Kim DY, Park KH, Jung MS, Huang B, Yuan HD, Quan HY, Chung SH. Ginsenoside Rh2(S) induces differentiation and mineralization of MC3T3-E1 cells through activation of the PKD/AMPK signaling pathways. Int J Mol Med 2011;28:753-759.
38. Liu J, Shiono J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. 20(R)-ginsenoside Rh2, not 20(S), is a selective os-teoclastgenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett 2009;19:3320-3323.
39. Cheng B, Li J, Du J, Lv X, Weng L, Ling C. Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways. Food Chem Toxicol 2012;50:1610-1615.
40. Kim DY, Park YG, Quan HY, Kim SJ, Jung MS, Chung SH. Ginsenoside Rd stimulates the differentiation and mineralization of osteoblastic MC3T3-E1 cells by activating AMP-activated protein kinase via the BMP-2 signaling pathway. Fitoterapia 2012;83:215-222.
41. Kim DY, Jung MS, Park YG, Yuan HD, Quan HY, Chung SH. Ginsenoside Rh2(S) induces the differentiation and mineralization of osteoblastic MC3T3-E1 cells through activation of PKD and p38 MAPK pathways. BMB Rep 2011;44:659-664.
42. He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS et al. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. Bone 2012;50:1207-1213.
43. Li XD, Chang B, Chen B, Liu ZY, Liu DX, Wang JS, Hou GQ, Huang DY, Du SX. Panax notoginseng saponins potentiate osteogenesis of bone marrow stromal cells by modulating gap junction intercellular communication activities. Cell Physiol Biochem 2010;26:1081-1092.
44. Li XD, Liu Z Y, Chang B, Liu DX, Chen B, Guo C, Wang YG, Xu JK, Huang D Y, Du SX. Panax notoginseng sapo-nins promote osteogenic differentiation of bone marrow stromal cells through the ERK and P38 MAPK signaling pathways. Cell Physiol Biochem 2011;28:367-376.
45. Gong YS, Chen J, Zhang QZ, Zhang JT. Effect of 17beta-oestradiol and ginsenoside on osteoporosis in ovariect-omised rats. J Asian Nat Prod Res 2006;8:649-656.
46. Monroe DG, Hawse JR, Subramaniam M, Spelsberg TC. Retinoblastoma binding protein-1 (RBP1) is a Runx2 co-activator and promotes osteoblastic differentiation. BMC Musculoskelet Disord 2010;11:104.
47. Kim KS, Pyo SK, Sohn EH. Immunomodulation of NK cell activity by red ginseng acidic polysaccharide (RGAP) in ovariectomized rats. J Ginseng Res 2009;33:99-103.
48. Yovel G, Shakhar K, Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol 2001;81:254-262.
49. Kropotov AV, Kolodnyak OL, Koldaev VM. Effects of Siberian ginseng extract and iprifavone on the development of glucocorticoid-induced osteoporosis. Bull Exp Biol Med 2002;133:252-254.
50. Kim HR, Cui Y, Hong SJ, Shin SJ, Kim DS, Kim NM, So SH, Lee SK, Kim EC, Chae SW et al. Effect of ginseng mixture on osteoporosis in ovariectomized rats. Immunopharmacol Immunotoxicol 2008;30:333-345.
51. Shen Y, Li YQ, Li SP, Ma L, Ding LJ, Ji H. Alleviation of ovariectomy-induced osteoporosis in rats by Panax no-toginseng saponins. J Nat Med 2010;64:336-345.
52. Li XD, Wang JS, Chang B, Chen B, Guo C, Hou GQ, Huang D Y, Du SX. Panax notoginseng saponins promotes proliferation and osteogenic differentiation of rat bone marrow stromal cells. J Ethnopharmacol 2011;134:268-274.
53. Brewer L, Williams D, Moore A. Current and future treatment options in osteoporosis. Eur J Clin Pharmacol 2011;67:321-331.
54. Yuan HD, Kim JT, Kim SH, Chung SH. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 2012;361:27-39.
55. Huang KC, Williams WM. The pharmacology of Chinese herbs. Boca Raton: CRC Press, 1999.
56. Kwak YS, Park JD, Yang JW. Present and its prospect of red ginseng efficacy research. Food Ind Nutr 2003;8:30-37.
57. Quan LH, Cheng LQ, Kim HB, Kim JH, Son NR, Kim SY, Jin HO, Yang DC. Bioconversion of ginsenoside Rd into compound K by Lactobacillus pentosus DC101 isolated from kimchi. J Ginseng Res 2010; 34:288-295.
58. Shin HY, Jeong HJ, An HJ, Hong SH, Um JY, Shin T Y, Kwon SJ, Jee SY, Seo BI, Shin SS et al. The effect of Panax ginseng on forced immobility time & immune function in mice. Indian J Med Res 2006;124:199-206.
59. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 2007;59:589-601.
60. Polan ML, Hochberg RB, Trant AS, Wuh HC. Estrogen bioassay of ginseng extract and ArginMax, a nutritional supplement for the enhancement of female sexual function. J Womens Health (Larchmt) 2004;13:427-430.
61. Kim NH, Lee HM, Choi CH, Lim SK. Clinical effect of Korean red ginseng on osteoporosis. J Ginseng Res 1998;22:114-121.